1. Home
  2. MFA vs ANL Comparison

MFA vs ANL Comparison

Compare MFA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFA Financial Inc.

MFA

MFA Financial Inc.

N/A

Current Price

$5.78

Market Cap

957.0M

Sector

Real Estate

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$10.80

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MFA
ANL
Founded
1997
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
957.0M
998.8M
IPO Year
1998
2022

Fundamental Metrics

Financial Performance
Metric
MFA
ANL
Price
$5.78
$10.80
Analyst Decision
Buy
Strong Buy
Analyst Count
7
7
Target Price
$12.58
★ $29.50
AVG Volume (30 Days)
★ 2.8M
268.1K
Earning Date
11-04-2026
08-14-2026
Dividend Yield
★ 25.90%
N/A
EPS Growth
★ 58.54
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$243.83
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.55
$0.88
52 Week High
$10.43
$17.25

Technical Indicators

Market Signals
Indicator
MFA
ANL
Relative Strength Index (RSI) 27.56 46.74
Support Level N/A $8.95
Resistance Level $6.87 $11.90
Average True Range (ATR) 0.24 0.99
MACD -0.05 0.25
Stochastic Oscillator 18.35 72.55

Price Performance

Historical Comparison
MFA
ANL

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: